Rice Hall James & Associates LLC purchased a new position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 75,469 shares of the company's stock, valued at approximately $3,805,000. Rice Hall James & Associates LLC owned about 0.12% of MoonLake Immunotherapeutics at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of the company. US Bancorp DE purchased a new position in shares of MoonLake Immunotherapeutics in the third quarter worth $44,000. Quarry LP raised its position in MoonLake Immunotherapeutics by 172.7% in the 2nd quarter. Quarry LP now owns 3,000 shares of the company's stock worth $132,000 after buying an additional 1,900 shares during the last quarter. Bellevue Group AG bought a new position in MoonLake Immunotherapeutics during the 1st quarter valued at about $221,000. DNB Asset Management AS boosted its holdings in shares of MoonLake Immunotherapeutics by 29.8% during the 2nd quarter. DNB Asset Management AS now owns 7,372 shares of the company's stock valued at $324,000 after acquiring an additional 1,694 shares during the last quarter. Finally, Handelsbanken Fonder AB boosted its holdings in shares of MoonLake Immunotherapeutics by 26.2% during the 3rd quarter. Handelsbanken Fonder AB now owns 13,000 shares of the company's stock valued at $655,000 after acquiring an additional 2,700 shares during the last quarter. 93.85% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
MLTX has been the topic of a number of research analyst reports. HC Wainwright restated a "buy" rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Tuesday, October 15th. Wolfe Research cut MoonLake Immunotherapeutics from an "outperform" rating to a "peer perform" rating in a research report on Monday, August 26th. Needham & Company LLC reissued a "buy" rating and issued a $62.00 target price on shares of MoonLake Immunotherapeutics in a research report on Thursday, September 12th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of MoonLake Immunotherapeutics in a research report on Monday, September 23rd. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $80.45.
Get Our Latest Analysis on MLTX
MoonLake Immunotherapeutics Trading Up 0.7 %
Shares of MLTX traded up $0.34 during trading hours on Friday, reaching $46.76. 244,073 shares of the stock traded hands, compared to its average volume of 379,743. MoonLake Immunotherapeutics has a 52-week low of $35.11 and a 52-week high of $64.98. The company has a market cap of $2.99 billion, a P/E ratio of -51.38 and a beta of 1.26. The company's 50-day moving average price is $49.11 and its two-hundred day moving average price is $45.15.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.11). During the same period in the previous year, the company earned ($0.23) earnings per share. On average, research analysts forecast that MoonLake Immunotherapeutics will post -1.54 EPS for the current year.
Insider Buying and Selling at MoonLake Immunotherapeutics
In other news, Director Simon Sturge sold 171,000 shares of the business's stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $53.72, for a total value of $9,186,120.00. Following the sale, the director now directly owns 171,980 shares in the company, valued at $9,238,765.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 12.02% of the stock is owned by company insiders.
MoonLake Immunotherapeutics Profile
(
Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Featured Stories
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
